1. Effect of reducing the dose of stavudine on body composition, bone density, and markers of mitochondrial toxicity in HIV-infected subjects: a randomized, controlled study;McComsey;Clinical Infectious Disease,2008
2. The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients;Milinkovic;Antiviral Therapy,2007
3. Reductions in stavudine dose might ameliorate mitochondrial-associated complications without compromising antiviral activity;Sanchez-Conde;HIV Clin Trials,2005 Jul-Aug
4. Symptomatic hyperlactateamia in adults on antiretroviral therapy: A single-center experience;Fabian;S Afr Med J,2008
5. Lange J Cooper D Kunanusont C Teeratakulpisarn S Ruxrungtham K Ungsedhapand C Phanuphak P Study HIV-NAT 002: the safety and efficacy of didanosine (DDI) +/- stavudine (d4T) in high/low dose combinations in an antiretroviral therapy naive Thai adult population with CD4 counts 150-350/mm 3 and predominantly infected with HIV-1 clade E International Conference on AIDS December 1998 ICA 12/98387016